Display options
Cite
Füth R, Dinh W, Nickl W, et al. Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol. 2009;14(3):e76-9
Füth, R., Dinh, W., Nickl, W., Bansemir, L., Barroso, M. C., Bufe, A., Sause, A., Scheffold, T., Krahn, T., Ellinghaus, P., & Lankisch, M. (2009). Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Experimental and clinical cardiology, 14(3), e76-9.
Füth, Reiner, et al. "Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease." Experimental and clinical cardiology vol. 14,3 (2009): e76-9.
Füth R, Dinh W, Nickl W, Bansemir L, Barroso MC, Bufe A, Sause A, Scheffold T, Krahn T, Ellinghaus P, Lankisch M. Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol. 2009;14(3):e76-9. PMID: 20098572; PMCID: PMC2807781.
Copy Download .nbib Format: NLM
Share it on

Exp Clin Cardiol. 2009;14(3):e76-9.

Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease.

Experimental and clinical cardiology

Reiner Füth, Wilfried Dinh, Werner Nickl, Lars Bansemir, Michael Coll Barroso, Alexander Bufe, Armin Sause, Thomas Scheffold, Thomas Krahn, Peter Ellinghaus, Mark Lankisch

Affiliations

  1. Helios Clinics Wuppertal, Heart Center;

PMID: 20098572 PMCID: PMC2807781

Abstract

OBJECTIVE: The development of diastolic dysfunction (DDF) is multifactorial. Possible mechanisms include metabolic disturbances, myocardial fibrosis, chronic inflammation and endothelial dysfunction. Recognizing early stages of DDF may help to identify patients at risk of developing symptomatic DDF. Therefore, biomarkers reflecting pathophysiological changes within the myocardium were investigated in patients with DDF.

METHODS: Seventy-seven patients submitted for coronary angiography with stable or suspected coronary artery disease (CAD) were consecutively enrolled. Those without known diabetes mellitus (DM) underwent a standardized oral glucose tolerance test. Echocardiography for the diagnosis of DDF was performed according to the European Society of Cardiology. Matrix metalloproteinase 2 (MMP-2) and soluble P-selectin (sP-selectin) serum concentrations were analyzed using the ELISA technique.

RESULTS: A total of 36% of patients had DM and 74% had CAD. The prevalence of DDF was higher in patients with DM (89% versus 74%) and CAD (84% versus 53%) (P<0.05). DDF in patients with DM was more severe with a significantly lower mitral annulus velocity of 6.5 cm/s versus 7.8 cm/s (P<0.01). Patients with DDF showed significantly higher sP-selectin (140.3 mug/L versus 107.6 mug/L, P<0.05) and MMP-2 (270.5 mug/L versus 224.7 mug/L, P<0.05) levels compared with those without DDF. There was a significant correlation between sP-selectin and MMP-2 (P=0.01), independent of the diagnosis of DM or CAD.

CONCLUSION: sP-selectin as a marker for platelet hyperactivity, inflammation and endothelial dysfunction, and MMP-2 as a marker for extracellular matrix turnover were significantly elevated in patients with DDF. This elevation was independent of coexisting DM or CAD. This observation may help to identify and monitor patients with DDF.

Keywords: Biomarkers; Coronary artery disease; Diabetes mellitus; Diastolic dysfunction; Glucose metabolism; Heart failure

References

  1. J Am Soc Echocardiogr. 1997 Jul-Aug;10(6):657-64 - PubMed
  2. Hypertension. 2006 Apr;47(4):711-7 - PubMed
  3. Endothelium. 2008 Jul-Aug;15(4):219-24 - PubMed
  4. Eur Heart J. 1997 Mar;18(3):470-9 - PubMed
  5. Acta Cardiol. 2009 Jun;64(3):329-34 - PubMed
  6. Eur J Heart Fail. 2007 Aug;9(8):795-801 - PubMed
  7. Circulation. 2006 May 2;113(17):2089-96 - PubMed
  8. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13835-40 - PubMed
  9. N Engl J Med. 2006 Jul 20;355(3):260-9 - PubMed
  10. Eur Heart J. 2003 Feb;24(4):320-8 - PubMed
  11. Eur Heart J. 2007 Oct;28(20):2539-50 - PubMed
  12. Endothelium. 2006 May-Jun;13(3):227-31 - PubMed
  13. Diabetologia. 2004 Mar;47(3):537-540 - PubMed
  14. J Vasc Res. 2001 Mar-Apr;38(2):153-62 - PubMed
  15. JAMA. 2003 Jan 8;289(2):194-202 - PubMed
  16. Circulation. 2007 Feb 20;115(7):888-95 - PubMed
  17. J Hypertens. 1998 Jul;16(7):1031-41 - PubMed
  18. Eur J Heart Fail. 2003 Aug;5(4):507-16 - PubMed
  19. Eur J Heart Fail. 2006 Mar;8(2):147-53 - PubMed
  20. J Am Coll Cardiol. 2001 Mar 15;37(4):1042-8 - PubMed
  21. Am J Med. 2004 Mar 8;116 Suppl 5A:64S-75S - PubMed

Publication Types